+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying JADE101, a drug administered by subcutaneous injection, to evaluate its safety and effectiveness in adults with Immunoglobulin A nephropathy IgAN, a kidney condition. This open-label Phase 2 trial aims to better understand how JADE101 works in this patient group and contributes to ongoing clinical knowledge. The study is sponsored by Jade Biosciences, Inc. Participants will receive JADE101 through subcutaneous injections. All participants receive the same treatment without a comparison group. The study will monitor participants from Day 1 through 100 weeks to assess safety and effects on urine protein levels. There is no placebo or blinding in this trial. During the study, participants will attend scheduled visits and undergo laboratory tests to monitor kidney function and protein levels in urine. Researchers will track any treatment-emergent side effects and changes in urine protein creatinine ratio to evaluate the drugs impact. Participants must comply with treatment plans and contraceptive and lifestyle requirements throughout the trial, which lasts approximately 100 weeks.

Age: 18Years - 60YearsAll GendersPhase 2
22 locations
E

Actively Recruiting

Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.

Age: 16Years +All GendersPhase 3
245 locations